RE: Investors after fundraise20 Mar 2022 23:52
DeepMatter (DMTR): Blue Chip Clients
One of the things this survey has done is to look at the winners of 2020 and then find analogous, and cheaper companies earlier in their life cycle. In the case of DeepMatter we have a company in the digitising chemistry space, which has started to grow its revenue pipeline and hence validate its IP via collaborations with the likes of AstraZeneca. In terms of the fundamental metrics here, the company raised £2.1m in July 2020, enough to last until at least 2023, with £4m in the bank as of August. With this backing the goal of the company is to create a shared data cloud with a platform which enables chemists from anywhere in the world to share details of their experiments in real time. This saves time and money for the scientists and also the organisations they work for. Apart from Astra, Glaxo, Novartis, BASF and Cancer Research are clients of DeepMatter. If your clients are blue chip, it rather makes you as a company blue chip by association. The founder Professor Lee Cronin has recently added to his shareholding, with respected investor Richard Griffiths also on the register at 8.9%
Does anyone remember reading this.